KWF Research & Implementation
The KWF Research & Implementation programme 2022 consists of two calls covering exploration research and development & implementation in the field of cancer. On this page we provide an overview of these upcoming calls from KWF. For further information, contact our funding experts.
KWF Research & Implementation Calls 2022 – 2023
Deadline: expected end of April/early May 2022
Basic research: The goal of basic research is to obtain essential insight into the origin and progression of cancer and its (psychosocial) effects, as well as basic principles underlying the prevention and treatment of cancer and relevant technological developments. Basic research does not focus directly on the possible application of this knowledge.
Credentialing: Credentialing (or collecting credentials, evidence, confirmation) aims at identifying factors, targets and leads that could influence or improve prevention, diagnostics, treatment and quality of life. Examples are the discovery of drugs or biomarkers and compound or drug screening. Observational and population studies are also part of credentialing, including cross-sectional research, retrospective and/or prospective cohort studies and case-control studies. The credentialing phase includes a first step towards validating the identified factors, targets or leads.
Development & Implementation
Expected deadline: October 2022 (opening in June 2022)
Creation of modality: The goal is the extensive characterisation and further development of new inventions/modalities until there is sufficient (in vitro and in vivo) evidence from model systems or retrospective data and sample sets, to start preparing for human evaluation. The development of psychosocial interventions is included in this research phase. Human participation in the development of inventions/modalities is possible in this phase when it is not meant for a validation in a human setting. Starting from this research phase, concrete solutions for specific problems and needs (including unmet medical needs) are developed and validated.
Preclinical research: The goal of preclinical research is the completion of all stages required to start the clinical/human evaluation of a new invention/modality in subjects, such as:
- The development of GMP/clinical-grade production, toxicity testing, pilot or technical testing, successful IND/IMPD/CE submission and regulatory/ethical aspects;
- Prospective analyses of the clinical feasibility of an invention or modality without performing the actual intervention (e.g. prospective biomarker studies without changing the actual treatment).
Clinical research: The goal of clinical research is to realize prospective clinical research, such as:
- a prospective clinical evaluation of a new invention/modality or assay/tool using a limited number of subjects;
- establishing the effectiveness of a new invention, dosage, off-label usage, combinations of modalities or psychosocial treatment;
- changes to treatment regimens associated with existing methodologies (including population checks) in a patient population.
Implementation research: Implementation research encompasses scientific studies on methods to promote the delivery and enhance the adoption of evidence-based interventions in (clinical) practice aligning with the main goals of KWF. A project proposal must have a research focus, including a scientific research question. Eligible projects focus on any aspect of Implementation research, including the factors affecting implementation, the process of implementation and the results of implementation. This also includes how to introduce potential solutions into a (health) system or how to promote their large scale use and sustainability. The purpose is to understand what, why, and how evidence based interventions/new methods work in “real world” settings, and to test approaches in order to improve them.
KWF – Impulse for smart measurement technology in oncologic patient care
Subsidy: Between €700,000 and 1,5M (this is just an indication)
Total Budget: €3-5M
Deadline: 31 August 2022 (opening on 4 July 2022)
Consortium: A consortium should include at least 1 technical researcher and at least 1 clinician from academic, top-clinical and research hospitals. Public/Private collaborations are possible. Involvement of (psycho)social researchers are encouraged and including patient participation throughout the project is a prerequisite.
Scope: The aim of this call is to stimulate further development and clinical implementation of smart measurement technology to provide diagnosis and monitoring of oncological patients in a minimal invasive manner. For that, KWF is looking for multidisciplinary teams that fulfil the unmet clinical need and can reach the next developmental phase on its way to daily practice. Projects should start from TRL2, and below are some examples of projects that are in scope:
- Smart measurement technology such as smartwatch, patches, minimal invasive blood test, tabletop devices;
- Repurposing of existing (validated) techniques for clinical questions;
- Development of new technology for unmet clinical needs;
- (Early) diagnosis of (recurrent) disease and monitoring during therapeutic interventions and/or patient selection for therapeutic interventions.
Further reading on the KWF Research & Implementation Programme